The productivity crisis in pharmaceutical R&D F Pammolli, L Magazzini, M Riccaboni Nature reviews Drug discovery 10 (6), 428-438, 2011 | 1217 | 2011 |
Economic and social consequences of human mobility restrictions under COVID-19 G Bonaccorsi, F Pierri, M Cinelli, A Flori, A Galeazzi, F Porcelli, ... Proceedings of the national academy of sciences 117 (27), 15530-15535, 2020 | 1138 | 2020 |
A comparison of US and European university-industry relations in the life sciences J Owen-Smith, M Riccaboni, F Pammolli, WW Powell Management science 48 (1), 24-43, 2002 | 801 | 2002 |
Technological change and network dynamics: lessons from the pharmaceutical industry L Orsenigo, F Pammolli, M Riccaboni Research policy 30 (3), 485-508, 2001 | 601 | 2001 |
Innovation and corporate growth in the evolution of the drug industry G Bottazzi, G Dosi, M Lippi, F Pammolli, M Riccaboni International journal of industrial organization 19 (7), 1161-1187, 2001 | 564 | 2001 |
Reputation and impact in academic careers AM Petersen, S Fortunato, RK Pan, K Kaski, O Penner, A Rungi, ... Proceedings of the National Academy of Sciences 111 (43), 15316-15321, 2014 | 317 | 2014 |
The growth of business firms: Theoretical framework and empirical evidence D Fu, F Pammolli, SV Buldyrev, M Riccaboni, K Matia, K Yamasaki, ... Proceedings of the National Academy of Sciences 102 (52), 18801-18806, 2005 | 257 | 2005 |
Global competitiveness in pharmaceuticals: a European perspective A Gambardella, L Orsenigo, F Pammolli | 222* | 2000 |
Persistence and uncertainty in the academic career AM Petersen, M Riccaboni, HE Stanley, F Pammolli Proceedings of the National Academy of Sciences 109 (14), 5213-5218, 2012 | 206 | 2012 |
Pharmaceuticals analyzed through the lens of a sectoral innovation system M McKelvey, L Orsenigo, F Pammolli Sectoral systems of innovation, 157-198, 2004 | 182 | 2004 |
A breath of fresh air? Firm type, scale, scope, and selection effects in drug development A Arora, A Gambardella, L Magazzini, F Pammolli Management Science 55 (10), 1638-1653, 2009 | 168 | 2009 |
The sustainability of European health care systems: beyond income and aging F Pammolli, M Riccaboni, L Magazzini The European Journal of Health Economics 13, 623-634, 2012 | 155 | 2012 |
Human mobility in response to COVID-19 in France, Italy and UK A Galeazzi, M Cinelli, G Bonaccorsi, F Pierri, AL Schmidt, A Scala, ... Scientific reports 11 (1), 13141, 2021 | 149 | 2021 |
The evolution of networks of innovators within and across borders: Evidence from patent data A Morescalchi, F Pammolli, O Penner, AM Petersen, M Riccaboni Research Policy 44 (3), 651-668, 2015 | 129 | 2015 |
A multi-level geographical study of Italian political elections from Twitter data G Caldarelli, A Chessa, F Pammolli, G Pompa, M Puliga, M Riccaboni, ... PloS one 9 (5), e95809, 2014 | 123 | 2014 |
Dynamic competition in pharmaceuticals: patent expiry, generic penetration, and industry structure L Magazzini, F Pammolli, M Riccaboni The European Journal of Health Economics, formerly: HEPAC 5, 175-182, 2004 | 123 | 2004 |
Innovation and competitiveness in European biotechnology F Pammolli, A Allansdottir, A Bonaccorsi, A Gambardella, M Mariani, ... Office for Official Publications of the European Communities, 2002 | 123 | 2002 |
Medical devices competitiveness and impact on public health expenditure F Pammolli, M Riccaboni, C Oglialoro, L Magazzini, G Baio, N Salerno | 122 | 2005 |
Is Europe evolving toward an integrated research area? A Chessa, A Morescalchi, F Pammolli, O Penner, AM Petersen, ... Science 339 (6120), 650-651, 2013 | 120 | 2013 |
On the size distribution of business firms J Growiec, F Pammolli, M Riccaboni, HE Stanley Economics Letters 98 (2), 207-212, 2008 | 119 | 2008 |